SRR1313112
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ADIPOGENESIS+0.510
- OXIDATIVE_PHOSPHORYLATION+0.460
- ESTROGEN_RESPONSE_EARLY+0.410
- ESTROGEN_RESPONSE_LATE+0.350
- FATTY_ACID_METABOLISM+0.340
- XENOBIOTIC_METABOLISM+0.330
- BILE_ACID_METABOLISM+0.260
- PEROXISOME+0.250
- CHOLESTEROL_HOMEOSTASIS+0.230
- MYOGENESIS+0.230
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.510
- ALLOGRAFT_REJECTION-0.490
- INTERFERON_GAMMA_RESPONSE-0.460
- MYC_TARGETS_V2-0.380
- G2M_CHECKPOINT-0.340
- INFLAMMATORY_RESPONSE-0.300
- KRAS_SIGNALING_UP-0.300
- COMPLEMENT-0.210
- E2F_TARGETS-0.210
- WNT_BETA_CATENIN_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8943024 | — | — | 0.806 |
| 2 | BS_N8J1DP02 | Posterior Fossa Ependymoma | — | 0.803 |
| 3 | SRR1313117 | — | B | 0.802 |
| 4 | SRR8518204 | — | F | 0.796 |
| 5 | C3L-01889 | — | cohortA2 | 0.788 |
| 6 | SRR8518245 | — | F | 0.769 |
| 7 | SRR8518241 | — | F | 0.765 |
| 8 | TCGA-78-7633-01A-11R-2066-07 | — | cohortA2 | 0.760 |
| 9 | BSR_07_0008_A3_S73 | — | B | 0.757 |
| 10 | SRR8518242 | — | F | 0.756 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ADIPOGENESIS | 0.510 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.460 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.410 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.350 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.330 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| PEROXISOME | 0.250 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.140 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.130 | Idelalisib | — uncovered |
| APOPTOSIS | 0.120 | Idelalisib | — uncovered |
| HYPOXIA | 0.110 | Idelalisib | — uncovered |